Xencor initiated with a Buy at EF Hutton

EF Hutton analyst Michael King initiated coverage of Xencor with a Buy rating and $42 price target. The analyst calls Xencor one of the biotech industry’s most prolific antibody and protein engineering companies. Advancement of multiple late-stage clinical assets are key to driving value in the shares in 2023, the analyst tells investors in a research note.